How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

803 results for

Valproic Acid Toxicity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment

, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device [IUD], birth control pills, or barrier device) during and for 2 months after trial. If male, use of an approved contraceptive method during the study and 2 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment. No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole. Exclusion Criteria (...) Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

42. The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver

who received TPN in the past 6 months. Patients with chronic liver disease, A1AT, Hemochromatosis, Wilson, Autoimmune, Toxic injury. Patients on anticoagulation therapy - Coumadin. Patients who use valproic acid therapy. Children, Pregnancy. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its (...) The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

43. Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration Full Text available with Trip Pro

compounds in addition to known environmental toxicants. The hits included the HSP90 inhibitor geldanamycin, the chemotherapeutic arsenic trioxide, the flame-retardant PBDE-99, the pesticide triadimefon and the histone deacetylase inhibitors valproic acid and trichostatin A. Transcriptome changes triggered by these substances in human neural crest cells were recorded and analysed here to answer three questions: (1) can toxicants be individually identified based on their transcript profile; (2) how can (...) Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration The in vitro test battery of the European research consortium ESNATS ('novel stem cell-based test systems') has been used to screen for potential human developmental toxicants. As part of this effort, the migration of neural crest (MINC) assay has been used to evaluate chemical effects on neural crest function. It identified some drug-like

2015 Archives of toxicology

44. DuoPlavin - clopidogrel / acetylsalicylic acid

DuoPlavin - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/196090/2010 CHMP ASSESSMENT REPORT FOR DuoPlavin International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001143 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) for the following indication: DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction

2010 European Medicines Agency - EPARs

45. DuoCover - clopidogrel / acetylsalicylic acid

DuoCover - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/195986/2010 CHMP ASSESSMENT REPORT FOR DuoCover International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001144 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) indication: DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoCover is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction in medically treated

2010 European Medicines Agency - EPARs

46. Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)

) to overcome resistance of CLL cells. Valproic acid (VPA) is an inhibitor of histone deacetylase (HDAC) used as an anticonvulsant and mood-stabilizing drug for decades. VPA mediates apoptosis in CLL cells through caspase activation. VPA shows toxicity toward CLL cells displaying alterations in the p53 pathway. The combination of VPA with fludarabine or 2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability, and significant increase in apoptosis. The highest index (...) Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2011 Clinical Trials

47. Valproic Acid With Chemoradiotherapy for Pancreatic Cancer

Center Information provided by: Soroka University Medical Center Study Details Study Description Go to Brief Summary: This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA) with concurrent chemoradiotherapy (CCRT) containing weekly gemcitabine in patients with unresectable locally advanced pancreatic cancer (ULAPC). All patients will be planned for three-dimensional conformal radiotherapy (3-DCRT). A total dose of 54 Gy will be delivered using 2 Gy daily (...) Valproic Acid With Chemoradiotherapy for Pancreatic Cancer Valproic Acid With Chemoradiotherapy for Pancreatic Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Valproic Acid With Chemoradiotherapy

2011 Clinical Trials

48. Toxic Epidermal Necrolysis (Diagnosis)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Diagnosis) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine.com

49. Toxic Epidermal Necrolysis (Overview)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Overview) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine.com

50. Toxicity, Valproate (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODE5MzE1LXRyZWF0bWVudA== processing > Valproate Toxicity Treatment & Management Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Treatment Approach Considerations Treatment of patients with valproate (valproic acid [VPA]) toxicity is mainly supportive, commonly including the following: Management of airway, breathing, and circulation (ABCs) Oxygenation Administration of intravenous (IV) fluids Monitoring (...) , Gaillard T, Brisou P, Vest P. Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity. Clin Toxicol (Phila) . 2012 Apr. 50(4):268. . Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) . 2006. 44(6-7):803-932. . Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem . 2013 Oct. 46(15):1323-38

2014 eMedicine Emergency Medicine

51. Toxicity, Valproate (Overview)

Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Overview Practice Essentials Although most cases of valproate (valproic acid [VPA]) overdose are benign, serious toxicity, including death, may occur after acute ingestion. Signs and symptoms Few historical features are specifically suggestive of valproate toxicity. The following information should be elicited if possible: Exact time (...) for mood stabilization, as opposed to its initial use predominantly as an anticonvulsant. In recent years, however, VPA exposures have stabilized at a lower rate, with 3211 single exposures reported in 2010 and 3060 reported in 2016. [ , ] The international frequency of valproic acid toxicity is unknown. Age-, sex-, and race-related demographics Although most acute VPA ingestions occur in persons older than 20 years, age does not influence outcomes after an acute ingestion. Children younger than 3

2014 eMedicine Emergency Medicine

52. Toxicity, Carbamazepine (Overview)

). The autoinduction process takes about 4 weeks. Carbamazepine stimulates the synthesis of many monooxygenase and conjugating enzymes, which leads to the metabolism of many medications. [ ] In terms of drug interactions, carbamazepine induces the metabolism of other anticonvulsant drugs such as phenytoin, clonazepam, primidone, valproic acid, and ethosuximide. This may lead to subtherapeutic levels of these drugs, especially phenytoin. In addition, carbamazepine reduces the duration and action of many therapeutic (...) Toxicity, Carbamazepine (Overview) Pediatric Carbamazepine Toxicity: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTAxMTI0MC1vdmVydmlldw== processing > Pediatric

2014 eMedicine Pediatrics

53. Toxicity, Carbamazepine (Diagnosis)

). The autoinduction process takes about 4 weeks. Carbamazepine stimulates the synthesis of many monooxygenase and conjugating enzymes, which leads to the metabolism of many medications. [ ] In terms of drug interactions, carbamazepine induces the metabolism of other anticonvulsant drugs such as phenytoin, clonazepam, primidone, valproic acid, and ethosuximide. This may lead to subtherapeutic levels of these drugs, especially phenytoin. In addition, carbamazepine reduces the duration and action of many therapeutic (...) Toxicity, Carbamazepine (Diagnosis) Pediatric Carbamazepine Toxicity: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTAxMTI0MC1vdmVydmlldw== processing > Pediatric

2014 eMedicine Pediatrics

54. Toxic Epidermal Necrolysis (Diagnosis)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Diagnosis) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine Emergency Medicine

55. Toxicity, Valproate (Follow-up)

Toxicity Follow-up Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Follow-up Further Outpatient Care After the patient's condition is stabilized and he or she is discharged, an ongoing relationship between the patient and a mental health professional is recommended if the overdose was intentional. Next: Further Inpatient Care Depending on level of toxicity, patients with valproic acid (...) to a psychiatric facility. However, this disposition highly depends on the patient's symptoms and the amount of ingestion. In one multicenter case series of 134 patients with valproic acid ingestions (80 with toxic VPA levels at admission), the mean hospital stay for all patients was 44.7 hours (standard deviation, 28 h). [ ] Previous Next: Complications Valproic acid is used in the treatment of mood disorders in addition to its use as an antiseizure medication. Emergency personnel must consider

2014 eMedicine Emergency Medicine

56. Toxic Epidermal Necrolysis (Overview)

include the following: Sulfonamides (4.5 cases per million users per week) Chloramphenicol Macrolides (eg, erythromycin) Penicillins Quinolones (eg, ciprofloxacin, [ ] trovafloxacin [ ] ) Anticonvulsants associated with TEN include the following: Phenobarbital Phenytoin [ ] Carbamazepine Valproic acid Lamotrigine TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported. NSAIDs (...) Toxic Epidermal Necrolysis (Overview) Toxic Epidermal Necrolysis (TEN): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjI5Njk4LW92ZXJ2aWV3 processing > Toxic Epidermal

2014 eMedicine Emergency Medicine

57. Toxicity, Valproate (Diagnosis)

Updated: Jan 03, 2018 Author: Asim A Abbasi, MD, FAAP; Chief Editor: Michael A Miller, MD Share Email Print Feedback Close Sections Sections Valproate Toxicity Overview Practice Essentials Although most cases of valproate (valproic acid [VPA]) overdose are benign, serious toxicity, including death, may occur after acute ingestion. Signs and symptoms Few historical features are specifically suggestive of valproate toxicity. The following information should be elicited if possible: Exact time (...) for mood stabilization, as opposed to its initial use predominantly as an anticonvulsant. In recent years, however, VPA exposures have stabilized at a lower rate, with 3211 single exposures reported in 2010 and 3060 reported in 2016. [ , ] The international frequency of valproic acid toxicity is unknown. Age-, sex-, and race-related demographics Although most acute VPA ingestions occur in persons older than 20 years, age does not influence outcomes after an acute ingestion. Children younger than 3

2014 eMedicine Emergency Medicine

58. Valproic acid Full Text available with Trip Pro

of valproate, leading to decreased valproate concentrations : may increase warfarin concentration and prolong bleeding time. : may increase zidovudine serum concentration and lead to toxicity. Overdose and toxicity [ ] Therapeutic range of valproic acid Form Lower limit Upper limit Unit Total (including ) 50 125 µg/mL or mg/l 350 700 μmol/L Free 6 22 µg/mL or mg/l 35 70 μmol/L Excessive amounts of valproic acid can result in sleepiness, , , , , , and death. In general, serum or plasma valproic acid (...) . Sztajnkrycer MD (2002). "Valproic acid toxicity: overview and management". J. Toxicol. Clin. Toxicol . 40 (6): 789–801. : . . Patsalos PN, Berry DJ (2013). "Therapeutic drug monitoring of antiepileptic drugs by use of saliva". Ther Drug Monit . 35 (1): 4–29. : . . Thanacoody RH (2009). "Extracorporeal elimination in acute valproic acid poisoning". Clin Toxicol . 47 (7): 609–616. : . . R. Baselt, Disposition of Toxic Drugs and Chemicals in Man , 8th edition, Biomedical Publications, Foster City, CA, 2008

2012 Wikipedia

59. Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line Full Text available with Trip Pro

, amiodarone, diclofenac, metformin, phenformin, and valproic acid) to LD(50) data (mg compound/mg cellular protein) showed that the variation in LD(50) values was generally less than that suggested by the original LC(50) data. Toxicological analysis of these six compounds in 3D spheroid culture (either published or presented here) demonstrated similar LD(50) values. Although in vitro 2D HepG2 data showed a poor correlation, the primary hepatocyte and 3D spheroid data resulted in a much higher degree (...) Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line Numerous publications have documented that the immortal cells grown in three-dimensional (3D) cultures possess physiological behavior, which is more reminiscent of their parental organ than when the same cells are cultivated using classical two-dimensional (2D) culture techniques. The goal of this study was to investigate whether this observation could be extended to the determination of LD

2012 Toxicological Sciences

60. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis (Abstract)

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) using a sequential trial design.Between April 2005 and January 2007, 163 ALS patients received VPA 1,500mg or placebo daily. Primary end point was survival. Secondary outcome

2009 EvidenceUpdates Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>